作者
Bao-Zhong Zhang, Hin Chu, Shuo Han, Huiping Shuai, Jian Deng, Ye-fan Hu, Hua-rui Gong, Andrew Chak-Yiu Lee, Zijiao Zou, Thomas Yau, Wutian Wu, Ivan Fan-Ngai Hung, Jasper Fuk-Woo Chan, Kwok-Yung Yuen, Jian-Dong Huang
发表日期
2020/10
期刊
Cell research
卷号
30
期号
10
页码范围
928-931
出版商
Springer Singapore
简介
Dear Editor, Coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 1 has resulted in over 13 million confirmed cases and more than 580,045 deaths across 218 countries and geographical regions as of July 16, 2020. This novel coronavirus primarily causes respiratory illness with clinical manifestations largely resembling those of SARS. However, neurological symptoms including headache, anosmia, ageusia, confusion, seizure, and encephalopathy have also been frequently reported in COVID-19 patients. 2, 3 In a study of 214 hospitalized COVID-19 patients in Wuhan, China, neurologic findings were reported in 36.4% of patients, and were more commonly observed in patients with severe infections (45.5%). 2 Similarly, a study from France reported neurologic findings in 84.5%(49/58) of COVID-19 patients admitted to hospital. 3 Importantly, a …
引用总数
学术搜索中的文章